financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
Cytokinetics Insider Sold Shares Worth $370,880, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cytokinetics Insider Sold Shares Worth $370,880, According to a Recent SEC Filing
Nov 13, 2024 4:26 PM

07:10 PM EST, 11/13/2024 (MT Newswires) -- Fady Ibraham Malik, EVP Research & Development, on November 12, 2024, sold 6,342 shares in Cytokinetics ( CYTK ) for $370,880. Following the Form 4 filing with the SEC, Malik has control over a total of 113,878 shares of the company, with 113,878 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1061983/000112760224027240/xslF345X05/form4.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Newmont Subsidiary Cuts Stake in Star Diamond to About 10%
Newmont Subsidiary Cuts Stake in Star Diamond to About 10%
Dec 20, 2024
06:00 AM EST, 12/20/2024 (MT Newswires) -- Newmont ( NEM ) late on Thursday said its subsidiary Newmont Canada FN Holdings ULC sold 9.5 million common shares of Star Diamond ( SHGDF ) in a private placement transaction for $190,000, or $0.02 per share. The sale pushed Newmont's ( NEM ) stake in Star Diamond ( SHGDF ) down to...
 Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected
Novo Nordisk's next-gen obesity drug CagriSema achieves lower weight loss than expected
Dec 20, 2024
LONDON/COPENHAGEN, Dec 20(Reuters) - Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected. The lower-than-expected weight loss from the drug candidate deals a blow to the Danish drugmaker's ambitions for a successor to its popular Wegovy more powerful than Eli...
 EU approves Nvidia's acquisition of Run:ai
EU approves Nvidia's acquisition of Run:ai
Dec 20, 2024
BRUSSELS (Reuters) - The European Commission said on Friday it has approved unconditionally Nvidia's ( NVDA ) $700 million bid for Run:ai. The EU's probe into the deal focused on practices that could strengthen Nvidia's ( NVDA ) control over GPUs, sought-after chips that divide and process computer tasks, but it concluded that the acquisition of Run:ai would not raise...
 EU approves Nvidia's acquisition of Run:ai
EU approves Nvidia's acquisition of Run:ai
Dec 20, 2024
BRUSSELS, Dec 20 (Reuters) - The European Commission said on Friday it has approved unconditionally Nvidia's ( NVDA ) $700 million bid for Run:ai. The EU's probe into the deal focused on practices that could strengthen Nvidia's ( NVDA ) control over GPUs, sought-after chips that divide and process computer tasks, but it concluded that the acquisition of Run:ai would...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved